Blog
About

3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although antiretroviral pre-exposure prophylaxis prevents HIV acquisition, it is not known if it alters HIV disease progression. This study assesses whether tenofovir gel impacted on disease progression among CAPRISA 004 microbicide trial seroconvertors.

          Related collections

          Author and article information

          Affiliations
          [1 ] *Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; †Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; ‡Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; §Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; ‖National Health Laboratory Service, South Africa; ¶AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa; and #Department of Epidemiology, Columbia University, New York, NY USA.
          Journal
          J. Acquir. Immune Defic. Syndr.
          Journal of acquired immune deficiency syndromes (1999)
          Ovid Technologies (Wolters Kluwer Health)
          1944-7884
          1525-4135
          Jan 01 2015
          : 68
          : 1
          25247433 10.1097/QAI.0000000000000367 4262710 NIHMS628172

          Comments

          Comment on this article